Presentation

Company Profile
Asarina Pharma is a Swedish biotech company developing Sepranolone for allopregnanolone-related stress, menstrual and neurological disorders. The product pipeline is built on over 40 years’ research into GABA hormones by the founder Torbjörn Bäckström. Asarina Pharma aims to use their new family of GAMSA compounds (GABA-A Modulating Steroid Antagonists) to deliver a new generation of efficacious and safe drugs for still widely untreated conditions. The upcoming studies are focusing on Tourette syndrome (TS) and Obsessive-Compulsive Disorder (OCD).

Recent highlights
In April, the company announced the last visit of the last patient in their Phase IIA study of Sepranolone in patients with Menstrual Migraine (MM). Topline results were reported in June, showing a favourable safety profile, but the drug did not achieve statistical significance in the primary and secondary efficacy endpoints compared to placebo. Asarina Pharma will no longer develop Sepranolone for MM but will continue with the substance for the treatment of TS and OCD. In May, the company announced that it received approval of CTA for Phase IIA study on patients with TS.

Outlook
The company remains committed to continue pursuing the development of Sepranolone for Tourette and Obsessive-Compulsive Disorder. The Tourette Syndrome Phase IIA study is expected to start in Q3 2021. The study will include 30 patients aged between 12 - 45 years who will receive 10 mg Sepranolone twice weekly for 12 weeks. Topline results are expected to be published by summer 2022.